Aortic coarctation medical therapy

(Redirected from Aortic Coarctation therapy)
Jump to navigation Jump to search

Aortic coarctation Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Aortic Coarctation from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Electrocardiogram

Chest X-Ray

CT

MRI

Angiography

Echocardiography

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Aortic coarctation medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Aortic coarctation medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Aortic coarctation medical therapy

CDC on Aortic coarctation medical therapy

Aortic coarctation medical therapy in the news

Blogs on Aortic coarctation medical therapy

Directions to Hospitals Treating Aortic coarctation

Risk calculators and risk factors for Aortic coarctation medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S.[2], Cafer Zorkun, M.D., Ph.D. [3]; Assistant Editor(s)-In-Chief: Kristin Feeney, B.S.[4] Hibatullah Abdul Aleem, M.B.B.S[5]

Overview

This microchapter covers pharmacologic management of coarctation of the aorta (CoA) across the age spectrum: (1) acute neonatal stabilization with prostaglandin E1; (2) management of paradoxical post-coarctectomy hypertension; (3) long-term antihypertensive therapy in native and repaired CoA; (4) blood pressure monitoring strategies; (5) cardiovascular risk factor modification; (6) endocarditis prophylaxis; and (7) special population considerations, including pregnancy and concurrent heritable aortopathy. Surgical and endovascular indications are covered in Aortic coarctation surgery; long-term surveillance protocols are covered in Aortic coarctation secondary prevention.


Medical Therapy

Neonatal Stabilization: Prostaglandin E1

Neonates with ductal-dependent CoA who develop hemodynamic compromise after ductal constriction require urgent stabilization with intravenous prostaglandin E1 (PGE1, alprostadil) to reopen or maintain ductus arteriosus patency and restore lower body perfusion.[1][2]

  • Initiation: PGE1 0.05–0.1 μg/kg/min by continuous IV infusion (FDA-recommended starting dose is 0.1 μg/kg/min; 0.05 μg/kg/min is an acceptable alternative; the Cochrane review cites a range of 0.025–0.1 μg/kg/min).[3] For neonates with echocardiographically confirmed ductal patency, low-dose initiation at 0.01–0.02 μg/kg/min may be effective while minimizing apnea risk (AHA Class IIa, LOE: C).[4] Ductal reopening typically occurs within 30 minutes to 2 hours. Confirm patency echocardiographically.
  • Maintenance: Wean to 0.01–0.025 μg/kg/min once ductal patency is established and the patient is clinically stable; lower maintenance doses reduce apnea risk without loss of efficacy.[4]
  • Adverse effects: Apnea (dose-dependent; most common >0.015 μg/kg/min), peripheral vasodilation, hypotension, fever; cortical hyperostosis with prolonged use.
  • Airway: Elective intubation before transport may be required; minimize concurrent respiratory depressants (opioids, benzodiazepines).
  • Supportive care: Ventilatory support for respiratory distress; inotropic support (dopamine, milrinone) for cardiogenic shock; correction of metabolic acidosis; diuretics for congestive heart failure.[5]

Definitive surgical repair is typically planned within 5–7 days after birth once fetal-to-neonatal transition is optimized. Emergent surgery or transcatheter intervention may be required in patients with treatment-resistant LV dysfunction or end-organ damage.[5]

Paradoxical Post-Coarctectomy Hypertension

Paradoxical hypertension occurs in approximately 50% of patients in the immediate postoperative period following CoA repair and follows a biphasic pattern:[6][7]

  • Phase 1 (first 24 hours): Predominantly sympathetically mediated. Elevated catecholamines and baroreceptor resetting drive systolic hypertension (plasma norepinephrine may rise from ~160 to ~657 pg/mL at 6 hours post-cross-clamp release).[8]
  • Phase 2 (24–72 hours): Renin-angiotensin system activation drives diastolic hypertension, fluid retention, and — in severe cases — mesenteric arteritis ("post-coarctectomy syndrome": abdominal pain, rarely bowel necrosis).[9]

Pharmacologic Management

Agent Role Dosing / Notes
Esmolol First-line; best-studied agent for pediatric post-repair hypertension (used off-label — FDA label states "safety and effectiveness in pediatric patients have not been established"[10]) 125–500 μg/kg loading dose over 1 minute, then continuous infusion; maintenance doses in post-coarctectomy patients may need to be substantially higher than typical adult dosing (mean ~700 μg/kg/min reported).[11] Multicenter double-blind RCT demonstrated safety and efficacy.[12]
Labetalol Attenuates paradoxical hypertension and suppresses renin-angiotensin activation Up to 20 μg/kg/min infusion[8]
Nicardipine Emerging preferred alternative to nitroprusside in infants Demonstrated noninferiority to nitroprusside with significantly lower cost[13]
Sodium nitroprusside Adjunct vasodilator; post-repair setting only FDA CONTRAINDICATION: nitroprusside is contraindicated for compensatory hypertension in unrepaired CoA (risks worsening lower body hypoperfusion). Its use in the immediate post-repair setting — obstruction relieved — is supported by clinical practice but is a distinct context. Increasingly being replaced by nicardipine.


Long-Term Antihypertensive Therapy

Hypertension is the most common long-term sequela of CoA — repaired or unrepaired — and is a major driver of premature coronary artery disease, heart failure, stroke, and aortic dissection.[14]

Guideline Recommendations

Guideline Recommendation COR LOE
2022 ACC/AHA Aortic Disease[15] Guideline-directed medical therapy (GDMT) is recommended for treatment of hypertension in patients with CoA 1 C-EO
2025 ACC/AHA ACHD[16] Target systolic BP <130 mmHg in adults with CoA — —
2017 ACC/AHA Hypertension (reaffirmed in 2025 synopsis)[17][18] Beta-blockers are recommended as preferred antihypertensive agents in patients with hypertension and thoracic aortic disease 1 C-EO

Choice of Agent

  • Beta-blockers are the most commonly used first-line agents. Persistent hypertension in CoA is driven in part by chronically elevated sympathetic activity and reduced baroreceptor sensitivity. Beta-blockers are supported as preferred agents for thoracic aortic disease by the 2017 ACC/AHA Hypertension Guideline (Class 1, C-EO), reaffirmed in the 2025 ACC/AHA Hypertension Guideline synopsis.[17][18] The 2022 ACC/AHA Aortic Disease Guideline rates beta-blockers for thoracic aortic aneurysm as Class 2a, LOE: C-LD.[15][19]
  • ACE inhibitors / ARBs are commonly added as second-line agents or used as alternatives. A randomized trial (n=51, ages 6–20) after successful CoA repair found that both atenolol and enalapril similarly reduced 24-hour systolic BP, but only enalapril significantly reduced LV mass index (47 ± 12 → 39.6 ± 10 g/m²·⁷; p=0.016), with no drug withdrawals due to adverse events versus 7.7% withdrawal rate in the atenolol group.[20]
  • Combination therapy is frequently required. A multicenter cross-sectional study (n=110 children after successful CoA repair) found BP control achieved in only 53% of treated patients; the dominant phenotype was isolated systolic hypertension (87.5% of uncontrolled cases), often at subtherapeutic doses.[21]

Critical principle: Before intensifying antihypertensive therapy, recoarctation must be excluded as a cause of persistent or recurrent hypertension. Evaluate for residual aortic arch obstruction — particularly if an upper-to-lower extremity BP gradient is present — before escalating medical therapy. If significant residual or recurrent CoA is identified, catheter-based or surgical reintervention should be considered.[15]

Blood Pressure Monitoring Strategies

Accurate BP assessment is fundamental to pharmacologic management of CoA.

  • Four-extremity BP measurement at initial evaluation; right arm and one lower extremity at routine visits (right arm preferred unless aberrant right subclavian artery is present).[15][16]
  • Ambulatory blood pressure monitoring (ABPM) is reasonable for diagnosis and monitoring of hypertension (2018 AHA/ACC ACHD: Class IIa, LOE: C-LD; reaffirmed in the 2025 ACC/AHA ACHD Guideline).[22][16] ABPM detects masked hypertension and nocturnal non-dipping — a marker of vascular dysfunction and future cardiovascular events. Resting office BP alone underestimates true systolic BP burden and can lead to undertreatment.[21]
  • Exercise stress testing evaluates for exercise-induced hypertension (peak exercise SBP >210 mmHg in males; >190 mmHg in females). Exercise-induced hypertension is common in adults with CoA and independently associated with LV hypertrophy and higher cardiovascular event risk regardless of resting BP. Exercise testing is reasonable every 5 years in patients with CoA and hypertension already on antihypertensive therapy. No consensus exists on whether to initiate antihypertensive therapy for isolated exercise-induced hypertension with normal resting and ambulatory BPs.[16]

Cardiovascular Risk Factor Modification

CoA is a lifelong vasculopathy, not merely a mechanical obstruction. Even after adequate repair, patients demonstrate endothelial dysfunction, increased arterial stiffness, and elevated sympathetic activity — all contributing to premature cardiovascular disease.[19][14]

  • Lifestyle modification: Sodium restriction; DASH-type dietary pattern; regular physical activity (individualized to underlying cardiac status); attainment of ideal body weight (BMI 18.5–24.9 kg/m²); moderation of alcohol consumption.[23]
  • ASCVD risk factor management: Premature coronary artery disease in CoA patients is multifactorial — hypertension, hyperlipidemia, type 2 diabetes, and inherent vascular dysfunction all contribute. Standard lipid and glucose management per general population guidelines should be applied.[16]

Endocarditis Prophylaxis

Per the 2018 AHA/ACC ACHD, 2008 ACC/AHA ACHD, and 2025 ACC/AHA ACHD Guidelines, patients with uncomplicated native or repaired CoA do not require routine endocarditis prophylaxis unless high-risk features are present:[22][24][16]

  • Prior history of infective endocarditis
  • Prosthetic valve (biological or mechanical)
  • Within 6 months of placement of prosthetic material (including stents)
  • Residual intracardiac shunts at or adjacent to prosthetic material
  • Uncorrected cyanotic heart disease

The 2021 AHA Scientific Statement on Prevention of Viridans Group Streptococcal IE further clarifies that uncomplicated repaired CoA without prosthetic material beyond 6 months does not warrant prophylaxis.[25]

Patients with CoA and coexisting bicuspid aortic valve do not currently meet AHA high-risk criteria for prophylaxis, though individual clinicians may exercise judgment given historical practice. Antibiotic-related risks should be considered before continuing a prophylaxis regimen in such cases.[26]

Special Populations

Pregnancy

Women with CoA (repaired or native) require antihypertensive management tailored to fetal safety. For pre-conception risk stratification, the modified WHO (mWHO) classification should be applied: CoA (repaired or unrepaired) without significant residual gradient or aortic aneurysm is generally classified as mWHO Class II; repaired CoA with residual gradient or aortic aneurysm, and native CoA without severe obstruction, is classified as mWHO Class III; severe native coarctation or recoarctation with significant obstruction is classified as mWHO Class IV, and pregnancy is generally advised against in this setting.[27][28] Hypertensive disorders of pregnancy occur in 5–30% of women with CoA depending on the population studied and repair status.[29][30] Per the 2025 ACC/AHA ACHD, 2018 AHA/ACC ACHD Guidelines, and the JACC Focus Seminar on Women with Congenital Cardiovascular Disease:[22]

  • Preferred agents: Labetalol (oral or IV) and nifedipine (extended-release) are the preferred antihypertensive agents in pregnancy for women with CoA.
  • Contraindicated: ACE inhibitors and ARBs are contraindicated in pregnancy (teratogenic; associated with fetal renal dysgenesis, oligohydramnios, and neonatal renal failure). Women on ACE inhibitors or ARBs should be transitioned to a pregnancy-safe agent before conception whenever possible.
  • Pre-eclampsia prevention: Consider low-dose aspirin (81 mg daily) initiated between 12 and 16 weeks of gestation (optimally before 16 weeks), given the elevated incidence of hypertensive disorders of pregnancy in women with CoA (USPSTF recommendation; ACOG Committee Opinion No. 743).[31][32]
  • Pre-conception risk assessment and multidisciplinary care (cardiology, maternal-fetal medicine) are recommended for all women with CoA contemplating pregnancy. Detailed pregnancy management is covered in the Secondary Prevention microchapter.

Calcium Channel Blockers

The 2022 ACC/AHA Aortic Disease Guideline states that it may be best to avoid long-term calcium channel blocker use in patients with Marfan syndrome and other inherited aortopathies, based on GenTAC registry data showing deleterious effects, unless necessary to achieve BP control.[15] While CoA is not a primary inherited aortopathy, this caution is relevant for CoA patients with concurrent heritable aortic conditions, and calcium channel blockers should be used with awareness of this context.

Key Updates from Prior Teaching

Topic Older Teaching Current Recommendation
BP target Variable, not specified Systolic <130 mmHg in adults (2025 ACC/AHA ACHD)[16]
BP monitoring Office BP sufficient ABPM and exercise testing are recommended adjuncts; resting BP underestimates burden[16]
Antihypertensive class "Beta-blocker is drug of choice" GDMT recommended (Class 1, C-EO per 2022 ACC/AHA); beta-blockers remain preferred for aortic disease broadly, but ACE inhibitors/ARBs offer LV mass regression benefit and are commonly used as first-line or add-on therapy[20][15]
Nitroprusside Listed as vasodilator without safety context Contraindicated in unrepaired CoA; nicardipine is an emerging preferred alternative post-repair[13]
Endocarditis prophylaxis Commonly given for CoA Not routinely recommended for uncomplicated CoA without high-risk features[22]
Disease concept Mechanical obstruction, "cured" by repair Lifelong vasculopathy; 20–70% develop late hypertension driven by intrinsic vascular dysfunction[19][33]

Areas of Uncertainty

  • Optimal antihypertensive drug class: No large RCTs compare beta-blockers vs. ACE inhibitors/ARBs specifically in CoA. The only CoA-specific randomized trial (n=51) favored enalapril for LV mass regression; beta-blocker preference is extrapolated from broader aortic disease data.[20]
  • Exercise-induced hypertension: No consensus on whether to initiate antihypertensive therapy in patients with exercise-induced hypertension who have normal resting and ambulatory BPs.[16]
  • Nitroprusside post-repair: The FDA contraindication for compensatory hypertension in unrepaired CoA creates labeling ambiguity regarding post-repair use where obstruction has been relieved; clinical practice supports use, but this is not explicitly addressed in labeling.
  • Pediatric BP targets: The 2025 ACC/AHA ACHD target of <130 mmHg systolic applies to adults; pediatric-specific thresholds are based on age/height percentile norms per the 2017 AAP Clinical Practice Guideline for High Blood Pressure in Children and Adolescents, but a formal post-CoA–specific pediatric target has not been established in current guidelines.

References

  1. ↑ Akkinapally S, Hundalani SG, Kulkarni M; et al. (2018). "Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions". Cochrane Database Syst Rev. 2: CD011417. doi:10.1002/14651858.CD011417.pub2. PMID 29376591.
  2. ↑ Heymann MA, Berman W, Rudolph AM, Whitman V (1979). "Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities". Circulation. 59 (1): 169–73. doi:10.1161/01.cir.59.1.169. PMID 758109.
  3. ↑ Food and Drug Administration (2026). "PROSTIN VR PEDIATRIC (alprostadil) label" (PDF).
  4. ↑ 4.0 4.1 Marino BS, Tabbutt S, MacLaren G; et al. (2018). "Cardiopulmonary resuscitation in infants and children with cardiac disease: a scientific statement from the American Heart Association". Circulation. 137 (22): e691–e782. doi:10.1161/CIR.0000000000000524. PMID 29566222.
  5. ↑ 5.0 5.1 Hysko K, Bertram H, Bobylev D, Horke A, Hansmann G (2025). "Advances in the treatment of neonatal coarctation of the aorta". Pediatrics. 155 (2): e2024067434. doi:10.1542/peds.2024-067434. PMID 39761814 Check |pmid= value (help).
  6. ↑ Rocchini AP, Rosenthal A, Barger AC, Castaneda AR, Nadas AS (1976). "Pathogenesis of paradoxical hypertension after coarctation resection". Circulation. 54 (3): 382–7. doi:10.1161/01.cir.54.3.382. PMID 788848.
  7. ↑ Sealy WC (1990). "Paradoxical hypertension after repair of coarctation of the aorta: a review of its causes". Ann Thorac Surg. 50 (2): 323–9. doi:10.1016/0003-4975(90)90768-2. PMID 2382060.
  8. ↑ 8.0 8.1 Charlton GA, Ladd DR, Friesen RM, Friesen RH (2020). "Labetalol infusion attenuates paradoxical hypertension and decreases plasma renin activity after repair of coarctation of the aorta in children". J Cardiothorac Vasc Anesth. 34 (12): 3348–3351. doi:10.1053/j.jvca.2020.05.027. PMID 32593586 Check |pmid= value (help).
  9. ↑ Fox S, Pierce WS, Waldhausen JA (1980). "Pathogenesis of paradoxical hypertension after coarctation repair". Ann Thorac Surg. 29 (2): 135–41. doi:10.1016/s0003-4975(10)61651-7. PMID 7352716.
  10. ↑ Food and Drug Administration (2023). "Esmolol Hydrochloride label" (PDF).
  11. ↑ Wiest DB, Garner SS, Uber WE, Sade RM (1998). "Esmolol for the management of pediatric hypertension after cardiac operations". J Thorac Cardiovasc Surg. 115 (4): 890–7. doi:10.1016/S0022-5223(98)70371-X. PMID 9535455.
  12. ↑ Tabbutt S, Nicolson SC, Adamson PC; et al. (2008). "The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: a multicenter, double-blind, randomized trial". J Thorac Cardiovasc Surg. 136 (2): 321–8. doi:10.1016/j.jtcvs.2007.09.086. PMID 18662571.
  13. ↑ 13.0 13.1 Wong RJ, Mruk AL, Grimaldi LM; et al. (2024). "Nicardipine or nitroprusside for postoperative blood pressure control in infants after surgery for congenital heart disease". Pediatr Crit Care Med. 25 (6): 538–546. doi:10.1097/PCC.0000000000003469. PMID 38477966 Check |pmid= value (help).
  14. ↑ 14.0 14.1 Januszewicz A, Mulatero P, Dobrowolski P; et al. (2022). "Cardiac phenotypes in secondary hypertension: JACC state-of-the-art review". J Am Coll Cardiol. 80 (15): 1480–1497. doi:10.1016/j.jacc.2022.08.714. PMID 36202538 Check |pmid= value (help).
  15. ↑ 15.0 15.1 15.2 15.3 15.4 15.5 Isselbacher EM, Preventza O, Hamilton Black J III; et al. (2022). "2022 ACC/AHA guideline for the diagnosis and management of aortic disease". J Am Coll Cardiol. 80 (24): e223–e393. doi:10.1016/j.jacc.2022.08.004. PMID 36334952 Check |pmid= value (help).
  16. ↑ 16.0 16.1 16.2 16.3 16.4 16.5 16.6 16.7 16.8 Gurvitz M, Krieger EV, Fuller S; et al. (2025). "2025 ACC/AHA/HRS/ISACHD/SCAI guideline for the management of adults with congenital heart disease". J Am Coll Cardiol. doi:10.1016/j.jacc.2025.09.006. PMID 40048948 Check |pmid= value (help).
  17. ↑ 17.0 17.1 Whelton PK, Carey RM, Aronow WS; et al. (2018). "2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults". J Am Coll Cardiol. 71 (19): e127–e248. doi:10.1016/j.jacc.2017.11.006. PMID 29133354.
  18. ↑ 18.0 18.1 Jones DW, Ferdinand KC, Taler SJ; et al. (2025). "2025 AHA/ACC guideline for the prevention, detection, evaluation, and management of high blood pressure in adults". J Am Coll Cardiol. 86 (18): 1567–1678. doi:10.1016/j.jacc.2025.05.007.
  19. ↑ 19.0 19.1 19.2 Lee MGY, Hemmes RA, Mynard J; et al. (2017). "Elevated sympathetic activity, endothelial dysfunction, and late hypertension after repair of coarctation of the aorta". Int J Cardiol. 243: 185–190. doi:10.1016/j.ijcard.2017.05.075. PMID 28414027.
  20. ↑ 20.0 20.1 20.2 Di Salvo G, Castaldi B, Gala S; et al. (2016). "Atenolol vs enalapril in young hypertensive patients after successful repair of aortic coarctation". J Hum Hypertens. 30 (6): 363–7. doi:10.1038/jhh.2015.87. PMID 26282186.
  21. ↑ 21.0 21.1 Sendzikaite S, Sudikiene R, Lubaua I; et al. (2022). "Antihypertensive therapy of late arterial hypertension in children following successful coarctation correction". J Hypertens. 40 (12): 2476–2485. doi:10.1097/HJH.0000000000003282. PMID 36040131 Check |pmid= value (help).
  22. ↑ 22.0 22.1 22.2 22.3 Stout KK, Daniels CJ, Aboulhosn JA; et al. (2019). "2018 AHA/ACC guideline for the management of adults with congenital heart disease: executive summary". J Am Coll Cardiol. 73 (12): 1494–1563. doi:10.1016/j.jacc.2018.08.1028. PMID 30400539.
  23. ↑ Bhatt AB, Foster E, Kuehl K; et al. (2015). "Congenital heart disease in the older adult: a scientific statement from the American Heart Association". Circulation. 131 (21): 1884–931. doi:10.1161/CIR.0000000000000204. PMID 25847991.
  24. ↑ Warnes CA, Williams RG, Bashore TM; et al. (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease". J Am Coll Cardiol. 52 (23): e143–e263. doi:10.1016/j.jacc.2008.10.001. PMID 19038677.
  25. ↑ Wilson WR, Gewitz M, Lockhart PB; et al. (2021). "Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association". Circulation. 143 (20): e963–e978. doi:10.1161/CIR.0000000000000969. PMID 33853405 Check |pmid= value (help).
  26. ↑ Bonow RO, Carabello BA, Chatterjee K; et al. (2008). "2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease". J Am Coll Cardiol. 52 (13): e1–142. doi:10.1016/j.jacc.2008.05.007. PMID 18848134.
  27. ↑ Davis MB, Arendt K, Bello NA; et al. (2021). "Team-based care of women with cardiovascular disease from pre-conception through pregnancy and postpartum: JACC Focus Seminar 1/5". J Am Coll Cardiol. 77 (14): 1764–1777. doi:10.1016/j.jacc.2021.02.009. PMID 33832604 Check |pmid= value (help).
  28. ↑ Elkayam U, Goland S, Pieper PG, Silverside CK (2016). "High-risk cardiac disease in pregnancy: Part I". J Am Coll Cardiol. 68 (4): 396–410. doi:10.1016/j.jacc.2016.05.048. PMID 27443437.
  29. ↑ Ramlakhan KP, Tobler D, Greutmann M; et al. (2021). "Pregnancy outcomes in women with aortic coarctation". Heart. 107 (1): 536–543. doi:10.1136/heartjnl-2020-317554. PMID 33122301 Check |pmid= value (help).
  30. ↑ Lindley KJ, Bairey Merz CN, Asgar AW; et al. (2021). "Management of women with congenital or inherited cardiovascular disease from pre-conception through pregnancy and postpartum: JACC Focus Seminar 2/5". J Am Coll Cardiol. 77 (14): 1778–1798. doi:10.1016/j.jacc.2021.02.026. PMID 33736829 Check |pmid= value (help).
  31. ↑ US Preventive Services Task Force, Davidson KW, Barry MJ; et al. (2021). "Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force recommendation statement". JAMA. 326 (12): 1186–1191. doi:10.1001/jama.2021.14781. PMID 34491129 Check |pmid= value (help).
  32. ↑ ACOG Committee on Obstetric Practice (2018). "ACOG Committee Opinion No. 743: low-dose aspirin use during pregnancy". Obstet Gynecol. 132 (1): e44–e52. doi:10.1097/AOG.0000000000002708. PMID 29939940.
  33. ↑ Ye L, Castaldi B, Cattapan I; et al. (2025). "Hypertension in aortic coarctation". Front Cardiovasc Med. 12: 1505269. doi:10.3389/fcvm.2025.1505269. PMID 39882558 Check |pmid= value (help).
Retrieved from "https://www.wikidoc.org/index.php?title=Aortic_coarctation_medical_therapy&oldid=1745018"